Spots Global Cancer Trial Database for A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
Official Title: A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Paclitaxel in Patients With Advanced Malignant Solid Tumors
Study ID: NCT01515306
Conditions
Study Description
Brief Summary: The purpose of this study is to investigate whether there are no clinically significant pharmacokinetic effects of concomitant ramucirumab (IMC-1121B) on paclitaxel by investigating the pharmacokinetics (PK) of each in participants with advanced malignant solid tumors. Part A of this study will investigate the potential of concomitant ramucirumab (IMC-1121B) to affect the pharmacokinetics of paclitaxel. Part B of this study will investigate the pharmacokinetics of ramucirumab (IMC-1121B) as monotherapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
ImClone Investigational Site, Ann Arbor, Michigan, United States
ImClone Investigational Site, Detroit, Michigan, United States
ImClone Investigational Site, New Brunswick, New Jersey, United States
ImClone Investigational Site, Cleveland, Ohio, United States
ImClone Investigational Site, Philadelphia, Pennsylvania, United States
ImClone Investigational Site, Seattle, Washington, United States
Contact Details
Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
